| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/21/2004 | US6794150 Detecting liver disorders in mammals; obtain sample, measure amount of marker, compare to control, diagnose liver disorder |
| 09/21/2004 | US6794144 Using random manipulation of the non-conserved region of sh3 rt-loop; nef proteins; for research, diagnostics, therapy and drug discovery |
| 09/21/2004 | US6794137 Detecting exposure of a cell to ultraviolet radiation; obtain cells, screen for preferential gene expression, monitor cells for adjusted tubulin protein expression |
| 09/21/2004 | US6793936 Delivers an active ingredient in a pulsed or bimodal manner. |
| 09/21/2004 | US6793924 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated t cells and thereby inhibits t cell activation of b cells |
| 09/21/2004 | US6793918 Genetic engineering; insertion of adenovirus vectors into cells |
| 09/21/2004 | CA2317673C Novel allylthiopyridazine derivatives and process for preparing the same |
| 09/21/2004 | CA2191871C Piperazine derivatives as 5ht1a antagonists |
| 09/21/2004 | CA2155843C Novel urea derivatives, their preparation and use |
| 09/21/2004 | CA2114017C Amide tetrazole acat inhibitors |
| 09/21/2004 | CA2028581C Compositions for treating fat deposits in humans |
| 09/17/2004 | CA2457989A1 The use of vitamin b6 to mitigate visual field defects associated with the use of gabaergic drugs in mammals |
| 09/16/2004 | WO2004078784A1 Novel gene relating to fibrotic conditions |
| 09/16/2004 | WO2004078764A1 Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent |
| 09/16/2004 | WO2004078751A1 Benzofuran derivative |
| 09/16/2004 | WO2004078741A1 Adiponectin expression promoter |
| 09/16/2004 | WO2004078723A1 Novel compound having 4-pyridylalkylthio group as substituent |
| 09/16/2004 | WO2004078719A1 Indole derivative compounds and drugs containing the compounds as the active ingredient |
| 09/16/2004 | WO2004078715A1 Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl |
| 09/16/2004 | WO2004078217A1 Bone calcification promoter |
| 09/16/2004 | WO2004078213A1 Composition for target substance introduction and method of target substance introduction |
| 09/16/2004 | WO2004078210A1 Preventive for adhesion following abdominal surgery |
| 09/16/2004 | WO2004078208A1 MEDICINAL USE OF MIP-3α INHIBITOR AND METHOD OF SCREENING BRAIN/NERVE CELL PROTECTIVE AGENT |
| 09/16/2004 | WO2004078195A1 Agent for converting intestinal cell into insulin-producing cell and remedy for diabetes |
| 09/16/2004 | WO2004078145A2 Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis |
| 09/16/2004 | WO2004078140A2 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| 09/16/2004 | WO2004077963A1 Processed plant product and method of producing the same |
| 09/16/2004 | WO2004062592A3 2-o sulfatase compositions and related methods |
| 09/16/2004 | WO2004052855A3 Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 09/16/2004 | WO2004052853A3 Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 09/16/2004 | WO2003105666A3 Method of treating ischemia reperfusion injury using adenosine receptor antagonists |
| 09/16/2004 | WO2003096974A3 ORIENTIA TSUTSUGAMUSHI TRUNCATED RECOMBINANT OUTER MENBRANE PROTEIN (r47) AND (r56) VACCINES DIAGNOSTICS AND THERAPEUTICS FOR SCRUB TYPHUS AND HIV INFECTION |
| 09/16/2004 | WO2003091207A3 Method of preparing amine stereoisomers |
| 09/16/2004 | WO2003088898A3 Compositions and methods for the diagnosis and treatment of tumor |
| 09/16/2004 | WO2003066063A8 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist |
| 09/16/2004 | WO2003066004A3 Therapeutic compounds |
| 09/16/2004 | WO2003065971A3 Non-myeloablative tolerogenic treatment with tyrphostins |
| 09/16/2004 | WO2003062265A3 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 09/16/2004 | WO2003053457A8 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon |
| 09/16/2004 | WO2003045318A3 Manipulation of cytokine levels using cd83 gene products |
| 09/16/2004 | WO2003045228A9 Methods for treating autoimmune disorders, and reagents related thereto |
| 09/16/2004 | WO2003028729A3 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 09/16/2004 | WO2002100827A3 Method for increasing the survival of dopamine secreting cells |
| 09/16/2004 | WO2002050097A3 Anti-allergic complex molecules |
| 09/16/2004 | US20040181063 such as 1-C-(5-N-benzyloxymethyl-4-methoxy pyrrolo[3,2-d]pyrimidin-7-yl)-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol; potent inhibitors of purine nucleoside phosphorylase and useful for suppressing T-cell function and/or treating and/or preventing infections caused by protozoan parasites |
| 09/16/2004 | US20040181062 Benzimidazole cyclooxygenase-2 inhibitor |
| 09/16/2004 | US20040181059 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 09/16/2004 | US20040181047 33 human secreted proteins |
| 09/16/2004 | US20040181041 Fusion protein capable of inducing programmed cell death for use in treatment cell proliferative diseases and infection |
| 09/16/2004 | US20040181039 Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| 09/16/2004 | US20040180964 anti-obestic activity; Neuropeptide Y antagonist |
| 09/16/2004 | US20040180963 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 09/16/2004 | US20040180959 --title-- |
| 09/16/2004 | US20040180956 calcium salt is calcium trifluoroacetate; to prepare medicaments with cytotoxic and antitumoral activity |
| 09/16/2004 | US20040180955 to establish a low circulating concentration of suramin in the patient of below about 200 mu, then administering cytotoxic agent |
| 09/16/2004 | US20040180952 Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same |
| 09/16/2004 | US20040180944 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
| 09/16/2004 | US20040180938 More preferred compound is (1Z,3E)-1-methyl-1-(4-carboxyphenyl)-2-methoxycarbonyl-3-(2-methylpyridin-4-yl)aminocarbonyl-4-(3-methoxyphenyl)butadiene; for the treatment of acute coronary symptoms |
| 09/16/2004 | US20040180934 Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists |
| 09/16/2004 | US20040180925 such as (S)-1-[2-(2-Pyrazinylamino)ethylamino]acetyl-2-pyrrolidinecarbonitrile dimethanesulfonate |
| 09/16/2004 | US20040180924 Novel heterocyclic derivatives and medicinal use thereof |
| 09/16/2004 | US20040180923 obesity, diabetes, male sexual dysfunction, and female sexual dysfunction |
| 09/16/2004 | US20040180921 Nitrogen compounds such as 2-benzofuran-2-yl-imidazo(1,2-a) pyridine administered as g protein coupled receptor antagonists for prophylaxis of psychological and neurodegenerative disorders, and as analgesics |
| 09/16/2004 | US20040180918 PDE 4 inhibitor (cilomilast) and an anticholinergic agent (tiotropium); asthma; copd |
| 09/16/2004 | US20040180914 5-Cyano-2-aminopyrimidine derivatives |
| 09/16/2004 | US20040180912 for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable |
| 09/16/2004 | US20040180911 for the treatment of a proliferative disease, such as a tumor |
| 09/16/2004 | US20040180910 Heterocycle carboxamides as antiviral agents |
| 09/16/2004 | US20040180901 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 09/16/2004 | US20040180899 tyrosine kinase inhibitors |
| 09/16/2004 | US20040180890 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same |
| 09/16/2004 | US20040180884 Dibenzocycloheptene compound |
| 09/16/2004 | US20040180881 Oxazolyl-pyrazole derivatives as kinase inhibitors |
| 09/16/2004 | US20040180878 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 09/16/2004 | US20040180876 Selective beta 2-adrenoreceptor agonists; rapid onset of action, long duration; such as 3-(4-{[6-{(-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzenesulfonamide; synthesis |
| 09/16/2004 | US20040180867 Daily administration of 17 beta-estradiol and every other day including norgestimate |
| 09/16/2004 | US20040180863 Novel, nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same |
| 09/16/2004 | US20040180846 Connexin enhances chemotherapy-induced apoptiosis in human cancer cells inhibiting tumor cell proliferation |
| 09/16/2004 | US20040180840 Blood brain barrier crossing and/or oral drug delivery; central nervous system tumors and cancer; such as etoposide attached to ethylene glycol oligomer or polymer; blood solubility, in vivo hydrolysis |
| 09/16/2004 | US20040180836 Blocking peptide for inflammatory cell secretion |
| 09/16/2004 | US20040180829 Compounds and methods for regulating bacterial growth and pathogenesis |
| 09/16/2004 | US20040180820 Spontaneous resorption of herniated disc; inducing vascular tubule formation using angiogenesis inducing substance |
| 09/16/2004 | US20040180818 adiponectin (adipose specific protein); suppressing fibrosis during regrowth; inhibiting TGFB and PDGF action on hepatic stellate cells; cirrhosis repair |
| 09/16/2004 | US20040180816 Combination comprising a p-gp inhibitor and an anti-epileptic drug |
| 09/16/2004 | US20040180434 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 09/16/2004 | US20040180052 Bind to AILIM (activation inducible lymphocyte immunomodulatory molecule, also referred to as ICOS (inducible co-stimulator); human monoclonal antibodies which bind to AILIM or a portion thereof; for treating disorders related to the delayed allergy |
| 09/16/2004 | US20040180007 Pharmaceutical chewing gum formulations |
| 09/16/2004 | DE20320528U1 Neue Kristallformen von Ondansetron und Arzneimittel, welche die neuen Formen enthalten New crystal forms of ondansetron and pharmaceutical compositions containing the new forms |
| 09/16/2004 | CA2517953A1 Novel gene relating to fibrotic conditions |
| 09/16/2004 | CA2517850A1 Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent |
| 09/16/2004 | CA2517145A1 Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 09/16/2004 | CA2517085A1 Adiponectin expression promoter |
| 09/16/2004 | CA2517081A1 Nitrogen-containing heterocyclic derivatives having 2-6, disubtituted styryl |
| 09/16/2004 | CA2512280A1 Benzofuran derivative |
| 09/15/2004 | EP1457556A1 Method of quantifying nucleic acid and kit for quantifying nucleic acid |
| 09/15/2004 | EP1457498A1 Novel peptide having angiotensin convertase inhibitory effect |
| 09/15/2004 | EP1457495A1 Adenosine A1 receptor agonists |
| 09/15/2004 | EP1457493A1 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists |
| 09/15/2004 | EP1457490A1 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 09/15/2004 | EP1457488A1 Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity |